Score:
6.5/10
Analyze what earned this score 🔥
Topper’s Copy
GS2
Science & Technology
10 marks
What are biosimilars? Discuss how the Biopharma Shakti initiative can help improve access to biological therapies in India.
Student’s Answer
Evaluation by SuperKalam
Demand of the Question
- Define biosimilars (their nature and characteristics)
- Discuss how BioPharma Shakti initiative improves access to biological therapies (mechanisms, impact pathways, implementation aspects)
What you wrote:
Biosimilars are "near-identical" versions of original biological medicines (biologics) derived from living organisms. Unlike simple chemical generics, they are complex molecules with no clinically meaningful differences in safety or efficacy.
Biosimilars are "near-identical" versions of original biological medicines (biologics) derived from living organisms. Unlike simple chemical generics, they are complex molecules with no clinically meaningful differences in safety or efficacy.
Suggestions to improve:
- Could introduce BioPharma Shakti briefly after defining biosimilars (e.g., "To address affordability barriers in biologics, the government launched BioPharma Shakti initiative in 2024 focusing on indigenous manufacturing capabilities")
What you wrote:
Access challenges:
* Cost -> Biologics are often 20x more expensive than traditional drugs.
* Complexity -> High barriers in manufacturing, cold-chain, and regulatory approval.
Impact of BioPharma Shakti (2026)
This ₹10,000 crore initiative scales India's biopharma ecosystem:
* Infrastructure -> Upgrades NIPERs and create a network of 1000+ clinical trial sites for faster development.
* Cost Reduction -> Incentivises MSMEs to manufacture fermentation-based bulk drugs, lowering retail prices.
* Regulatory Speed -> Strengthens the CDSCO with a dedicated scientific cadre to match global approval timelines.
* Self-Reliance -> Reduces import dependence for high-value therapies like insulin and monoclonal antibodies.
Access challenges:
* Cost -> Biologics are often 20x more expensive than traditional drugs.
* Complexity -> High barriers in manufacturing, cold-chain, and regulatory approval.
Impact of BioPharma Shakti (2026)
This ₹10,000 crore initiative scales India's biopharma ecosystem:
* Infrastructure -> Upgrades NIPERs and create a network of 1000+ clinical trial sites for faster development.
* Cost Reduction -> Incentivises MSMEs to manufacture fermentation-based bulk drugs, lowering retail prices.
* Regulatory Speed -> Strengthens the CDSCO with a dedicated scientific cadre to match global approval timelines.
* Self-Reliance -> Reduces import dependence for high-value therapies like insulin and monoclonal antibodies.
Suggestions to improve:
- Could explain biosimilars' access mechanism (e.g., "Biosimilars typically cost 30-40% less than reference biologics due to abbreviated clinical trial requirements, as they don't need to repeat full Phase I-III trials")
- Can add patient-centric outcomes (e.g., "The initiative targets expanding coverage under PM-JAY and Ayushman Bharat Digital Mission for biologics like trastuzumab for cancer treatment, currently accessible to less than 15% of eligible patients")
- Could mention specific biosimilar examples already developed (e.g., "India already exports biosimilars like Bevacizumab and Rituximab; BioPharma Shakti aims to develop 20+ new molecules domestically")
What you wrote:
BioPharma Shakti bridges the "accessibility gap" by localising the value chain. It ensures immediate affordability through biosimilars while fostering long-term indigenous innovation, securing India's health sovereignty.
BioPharma Shakti bridges the "accessibility gap" by localising the value chain. It ensures immediate affordability through biosimilars while fostering long-term indigenous innovation, securing India's health sovereignty.
Suggestions to improve:
- Could add implementation challenges or way forward (e.g., "Success depends on physician awareness programs about biosimilar interchangeability and state-level procurement reforms to prioritize indigenous biologics in essential medicine lists")
You've demonstrated good structure and included specific details like budget figures. However, the core mechanism of how biosimilars improve access is entirely missing—this is a critical demand. Your BioPharma Shakti discussion needs more patient-outcome focus rather than just infrastructure listing. Strengthen the linkage between policy provisions and actual therapeutic access.
Demand of the Question
- Define biosimilars (their nature and characteristics)
- Discuss how BioPharma Shakti initiative improves access to biological therapies (mechanisms, impact pathways, implementation aspects)
What you wrote:
Biosimilars are "near-identical" versions of original biological medicines (biologics) derived from living organisms. Unlike simple chemical generics, they are complex molecules with no clinically meaningful differences in safety or efficacy.
Biosimilars are "near-identical" versions of original biological medicines (biologics) derived from living organisms. Unlike simple chemical generics, they are complex molecules with no clinically meaningful differences in safety or efficacy.
Suggestions to improve:
- Could introduce BioPharma Shakti briefly after defining biosimilars (e.g., "To address affordability barriers in biologics, the government launched BioPharma Shakti initiative in 2024 focusing on indigenous manufacturing capabilities")
More Challenges
View All- View Challenge
GS2
International Relations
14 Aug, 2026
Power trade is emerging as an important instrument of India’s neighbourhood diplomacy. Examine how electricity cooperation with Bangladesh, Nepal and Bhutan can advance India’s strategic and economic interests while promoting regional integration.
- View Challenge
GS2
Indian Polity
Yesterday
The FCRA Amendment Bill, 2026 seeks to strengthen state oversight over foreign-funded organisations while raising concerns about civil society autonomy. Critically examine.
- View Challenge
GS3
Economy
12 Aug, 2026
The next phase of India's MSME growth lies not merely in creating more enterprises, but in clustering them. Examine how a cluster-based approach can enhance the productivity and global competitiveness of Indian MSMEs.
SuperKalam is your personal mentor for UPSC preparation, guiding you at every step of the exam journey.
Download the App
STUDY RESOURCES
CONTACT US
ⓒ Snapstack Technologies Private Limited